Evidence map›Paper›PMID 29777421›Full record

ReviewClinical & experimental metastasis2018

Lymph node metastasis in melanoma: a debate on the significance of nodal metastases, conditional survival analysis and clinical trials.

Mark B Faries, Dale Han, Michael Reintgen, Lauren Kerivan, Douglas Reintgen, Corrado Caracò

Abstract readReview
In one paragraph

Review in Clinical & experimental metastasis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. A vascularizedMaterials today. Bio · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Detection of cancer metastasis: past, present and future.Clinical & experimental metastasis · 2022
    Review
  12. Tumor-Derived Exosomes Modulate Primary Site Tumor Metastasis.Frontiers in cell and developmental biology · 2022
    Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Mark B FariesThe Angeles Clinic and Research Institute, 11800 Wilshire Blvd, Suite 300, Los Angeles, CA, USA. mfaries@theangelesclinic.org.ORCID 0000-0003-1752-7282
Dale HanSection of Surgical Oncology, Department of Surgery, Yale University School of Medicine, New Haven, CT, USA.
Michael ReintgenMorsani School of Medicine, University of South Florida, Tampa, FL, USA.
Lauren KerivanMorsani School of Medicine, University of South Florida, Tampa, FL, USA.
Douglas ReintgenMorsani School of Medicine, University of South Florida, Tampa, FL, USA.
Corrado CaracòIstituto Nazionale Tumori "Fondazione Pascale", Naples, Italy.
University of South Florida · USCedars-Sinai Medical Center · USIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITYale University · US

Funding

Multicenter Selective Lymphadenectomy Trial (MSLT II) in MelanomaR01CA189163 · NCI · SAINT JOHN'S CANCER INSTITUTE · PI FARIES, MARK B · 2014 to 2018
$8.1M
NCI NIH HHS R01 CA189163
6 · The paper itself

Abstract

While there is no doubt that regional lymph node metastases are an enormously important factor in melanoma staging and treatment, the biology behind this significance and its precise implications for treatment planning have been a leading controversy in melanoma and other solid tumors for over a century. Recent clinical data, including data from prospective randomized clinical trials have refined our understanding of the process of nodal metastases and the advantages and disadvantages of different clinical management strategies. This review presents two points of view in this debate and discusses the results of new data analyses as well as pivotal clinical trials informing the discussion.

Indexed as

Lymphatic MetastasisLymph Node ExcisionClinical Trials as TopicHumansMelanomaSentinel Lymph Node BiopsySkin NeoplasmsClinical trialLymphatic mappingMelanomaSentinel lymph nodeSurgical oncology

Identifiers

PMID29777421
PMCPMC6202130
OpenAlexW2803266876

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.